$BMY posts its earnings report demonstrating solid execution amidst ongoing challenges. Key highlights include a revenue growth of 9% in Q4 and a focus on operational excellence, with an expected 2025 revenue of ~$45.5 billion. Risks include significant LOEs impacting the legacy portfolio, particularly for Revlimid. Noteworthy projections for non-GAAP EPS are between $6.55 to $6.85. Future growth may hinge on new therapies like Cobinfi and strengthened market positions. 🧬📈 Check details at valueverge.com/BMY.